Skip to main content

Table 2 Protective efficacy of WNIG, IVIG-IL and IVIG-US in mice infected with 10–20 LD50 of WNV NY99

From: Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

Treatment (mg/mouse)

Specific Ab dosea

Percent survival (live/treated)

No treatment

0

7 (1/14)b

WNIG (0.1 mg)

15

94 (15/16)c

IVIG-IL (0.1 mg)

1.3

44 (7/16)

WNIG (0.5 mg)

76

100 (16/16)

IVIG-IL (0.5 mg)

7

87 (14/16)

WNIG (2.0 mg)

304

100 (8/8)

IVIG-IL (2.0 mg)

27

88 (7/8)

IVIG-US (2.0 mg)

7

63 (5/8)

  1. Groups of 4–5 week-old BALB/c mice were treated i.p. with different amounts of WNIG or IVIG-IL, 4 h after injection of 10–20 LD50 of West Nile virus. Animals were observed daily for mortality for 21 days. aArbitrary units of anti-WNV antibodies per mouse (as assessed by ELISA, see Methods). bp < 0.039, as compared to all treatment groups. cp = 0.006, as compared to the IVIG-IL (0.1 mg) group.